Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).

By J. Schachter, Antoni Ribas, Georgina V. Long, A. Arance, J. Grob, L. Mortier, A. Daud, M. Carlino, C. McNeil, M. Lotem and 10 more. The Lancet, 2017

1,099 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Ophthalmology

View Paper: https://www.semanticscholar.org/paper/85b08531e06216c96d1414282adabb35ccb68337